Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 434-280-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Wistar rats were treated with 434 -280 -4 for 28 -consecutive dats or until termination by oral gavage at dose levels of 0, 30, 100 and 300 mg/kg/day.
Intercurrent deaths
Thehighest dose of 300 mg/kg /day resulted in deaths and moribundity. Two females were found dead on study day 11. Furthermore, two males and one female were killed in extremis on day 10. Remaining males and females treated at 300 mg/kg/day (main and recovery groups) were sacrificed for humane reasons on day 11. The control recovery groups were sacrificed on the same day for sceintific reasons.. Clininical signs in these animals consisted of emaciation, hunched posture, breathing rales, pilo-erection, salivation, chromodacryorrhoea, lean appearance, squeakig, lethargy, ncoordinated moverments, yellow discolouration of the skin, pale ears, dehydration, ptosis and hypothermia. Reduced body weight gain and food intake was also noted. At the clinical labortaory investigations several findings relating to emaciation and the poor condition of the high dose animals were found.
Animals surviviing until planned sacrifice
At 100 mg/kg/day at the terminal sacrifice, histiocytosis in the mesenteric lymph node was noted. In the smalll intestine, foamy macrophages in the villi at minimal to moderate degree were noted in several rats at 100 mg/kg/day at terminal sacrifice. These effects were also accompanied by higher white bllod cell counts and hihger neutrophil counts in both sexes. Reduced body weight gain adn food intake was also noted in males at 100 mg/kg/day. Higher platelet counts and higher red blood cell counts were considered to be a secondary effect, probably caused by stimulation of the bone marrow. Chromodacryorrhoea wa pbserved during the last week of the treatment in two females att 100 mg/kg/day.
At 30 mg/kg/day higher nuetrophil counts were noted in males, but were note accompanied by higher whire blood cell counts. Higher white blood cell counts were noted in females, but were not accompanied by higher neurotphil counts. Additionally, no supportive effects were found at the macroscopic or microscopic examinations; therefore these changes were not regarded as toxicologically relevant.
No inhibition of cholinesterase was found at any dose level. Plasma cholinesterase was inhibited by 51% and 69% in males and females at 300 mg/kg/day, by 9% and 46% in males and females at 100 mg/kg/day and 5% and 12% in males and females at 30 mg/kg/dat and in males at 100 mg/kg/day was not considered to be significant.
From the results presented in the report a definitive No Observed Adverse Effect Level (NOAEL) for subchronic toxicity for 434 -280 -4of 30 mg/kg/was established.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 30 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Wistar rats were treated with EC434 -280 -4 for 28 -consecutive dats or until termination by oral gavage at dose levels of 0, 30, 100 and 300 mg/kg/day.
Intercurrent deaths
Thehighest dose of 300mg/kg /day resulted in deaths and moribundity. Two females were found dead on study day 11. Furthermore, two males and one female were killed in extremis on day 10. Remaining males and females treated at 300 mg/kg/day (main and recovery groups) were sacrificed for humane reasons on day 11. The control recovery groups were sacrificed on the same day for sceintific reasons.. Clininical signs in these animals consisted of emaciation, hunched posture, breathing rales, pilo-erection, salivation, chromodacryorrhoea, lean appearance, squeakig, lethargy, ncoordinated moverments, yellow discolouration of the skin, pale ears, dehydration, ptosis and hypothermia. Reduced body weight gain and food intake was also noted. At the clinical labortaory investigations several findings relating to emaciation and the poor condition of the high dose animals were found.
Animals surviviing until planned sacrifice
At 100 mg/kg/day at the terminal sacrifice, histiocytosis in the mesenteric lymph node was noted. In the smalll intestine, foamy macrophages in the villi at minimal to moderate degree were noted in several rats at 100 mg/kg/day at terminal sacrifice. These effects were also accompanied by higher white bllod cell counts and hihger neutrophil counts in both sexes. Reduced body weight gain adn food intake was also noted in males at 100 mg/kg/day. Higher platelet counts and higher red blood cell counts were considered to be a secondary effect, probably caused by stimulation of the bone marrow. Chromodacryorrhoea wa pbserved during the last week of the treatment in two females att 100 mg/kg/day.
At 30 mg/kg/day higher nuetrophil counts were noted in males, but were note accompanied by higher whire blood cell counts. Higher white blood cell counts were noted in females, but were not accompanied by higher neurotphil counts. Additionally, no supportive effects were found at the macroscopic or microscopic examinations; therefore these changes were not regarded as toxicologically relevant.
No inhibition of cholinesterase was found at any dose level. Plasma cholinesterase was inhibited by 51% and 69% in males and females at 300 mg/kg/day, by 9% and 46% in males and females at 100 mg/kg/day and 5% and 12% in males and females at 30 mg/kg/dat and in males at 100 mg/kg/day was not considered to be significant.
From the results presented in the report a definitive No Observed Adverse Effect Level (NOAEL) for subchronic toxicity for EC 434 -280 -4 of 30 mg/kg/was established.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.